Nebulizers Market is expected to reach US$ 1315.57 million by 2031

COPD Segment Expected to Hold Significant Share of Nebulizers Market During 2023–2031 

According to our new research study on "Nebulizers Market Forecast (2021–2031), Global Share, Trend, and Growth Opportunity Analysis – by Type, Application, End- User, and Geography," the market was valued at US$ 815.88million in 2023 and is expected to reach US$ 1315.57 million by 2031; it is estimated to record a CAGR of 6.2% during 2023–2031. The surging prevalence of chronic respiratory diseases and increasing demand for respiratory devices for home care settings are the factors propelling the nebulizers market growth. However, high equipment costs and strict regulatory frameworks impede the growth of the market.

The growing prevalence of chronic respiratory diseases (CRDs) propels the nebulizers market size. As per the Office of Disease Prevention and Health Promotion (ODPHP), ~14.8 million adults were diagnosed with COPD in 2020, in the US. The National Health Service (NHS) states that ~1.17 million people in the UK were diagnosed with COPD in 2021, representing ~1.9% of the total population.  CRDs are not curable; however, various treatments, including nebulizer therapy, can help open the air passages, improve shortness of breath, control symptoms, and improve the daily life of those living with these conditions. One of the treatments includes nebulizer therapy. This method enables the delivery of drugs directly to the airways and plays a crucial role in the management of CRDs. For instance, in an article published in PubMed Central in August 2020, a single-center study was conducted to investigate the pharmacokinetics and bioavailability of a solution of cromolyn sodium PA101 delivered via eFlow nebulizer in healthy volunteers, indolent systemic mastocytosis (ISM) patients, and patients with mild allergic asthma. The study concluded that a novel high-concentration PA101 solution administered via an eFlow nebulizer showed high systemic bioavailability. This formulation was found to be safe and well-tolerated by all study participants. Additionally, compared to IntalTM nebulizer and Nalcrom oral solutions, the systemic exposure was up to 8 and 11-fold higher with PA101 40 mg inhaled via eFlow nebulizer.

Nebulizers Market, by Region, 2023 (%)

Source: The Insight Partners Analysis

Further, air pollution, smoking, and frequent exposure to toxins are factors increasing the prevalence of CRD cases. According to COPD Foundation, smoking is the primary cause of COPD in the US.

Thus, the surging prevalence of chronic respiratory diseases, cases of smoking, and frequent exposure to pollutants are propelling the demand for respiratory devices for home care settings, thereby driving the nebulizers market growth.

Nebulizers Market Analysis Based on Market Trends:

Changes in nebulizer technology are driven by clinical needs and the development of new pharmacological agents, which require special techniques and performance characteristics. Due to strong economic pressures to optimize the delivery of newer medications, the development of innovative delivery devices such as transmucosal drug delivery systems for nebulization therapies has upscaled. With new medical knowledge and effective medicines, treatment with a wide range of nebulizers continues to advance. These advancements in nebulizer technology have led to the creation of mesh nebulizers that use micropump technology to produce aerosols. In addition to the numerous advantages of nebulizers, the growing number of product approvals and developments will likely strengthen the demand in the coming years. As per company press releases, a few major developments and approvals are listed below:

• In July 2021, HCmed Innovations received US Food and Drug Administration (FDA) approval for Pulmogine Vibrating Mesh Nebulizer. It uses HCmed's advanced technology to convert liquid medication into tiny aerosol particles that can be directly delivered to the airways, relieving respiratory disease discomfort. Additionally, the device is portable and easy to use, making it a convenient solution for patients who require inhalation treatment.
• In June 2020, Respira Technologies, Inc. launched its RespiRx drug delivery device platform. This novel platform is an ultra-portable handheld vibrating mesh nebulizer (VMN) for local and systemic treatment for various indications, including asthma and COPD. RespiRx offers a pre-filled cartridge that contains a disposable piezo element and the drug compound suspended in an aqueous solution. This format is designed for patients' convenience, eliminating errors and misuse due to improper cleaning. The cartridge is programmable to deliver precise doses and comes equipped with Bluetooth technology to track dose delivery, measure data, and collect electronic medical records for healthcare providers.

Therefore, such technological advancements by various market players and product approvals are anticipated to bring new nebulizers market trends in the coming years.

Segmental Analysis:

By product, the nebulizers market is segmented into jet nebulizers, ultrasonic nebulizers, and mesh nebulizers. The jet nebulizers segment held the largest market share in 2023 and is projected to register the highest CAGR during 2023–2031.

The market, by application, is segmented into COPD, asthma, cystic fibrosis, and others. The COPD segment is anticipated to hold the largest market share in 2023.

Based on end- user, the market is segmented into hospitals and clinics, emergency centers, and home care settings. The hospitals and clinics segment held the largest nebulizers market share in 2023. The home care settings segment is expected to register the highest CAGR from 2023 to 2031.   

The scope of the global nebulizers market report includes the assessment of the market performance in Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), North America (the US, Canada, and Mexico), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is anticipated to register the highest CAGR during 2023–2031. This is attributed to developing healthcare infrastructure in emerging markets, rising healthcare expenditure, lucrative reimbursement policies, and increasing emphasis on better patient outcomes in the region.

A few initiatives taken by key players operating in the global nebulizers market are listed below:

1. In December 2021, Cipla Limited introduced an initiative to improve access to nebulization therapy for managing acute asthma in India's rural primary healthcare centers with its vast presence throughout the care continuum and a broad range of drug–device combinations and treatments.
2. In March 2021, PARI Pharma GmbH launched its LAMIRA Nebulizer System, which has been authorized to deliver ARIKAYCE (amikacin liposome inhalation suspension) in Japan. This system uses advanced aerosol delivery systems based on eFlow Technology and features a customized medication reservoir that can hold a full dose of 8.4 ml. 

OMRON Healthcare, Inc; Koninklijke Philips N.V.; PARI GmbH; Vectura Group Ltd; Drive DeVilbiss International; Briggs Healthcare; GF Health Products, Inc.; GE Healthcare; Agilent Technologies, Inc; Terumo Corporation; and Trudell Medical International are among the leading companies profiled in the nebulizers market report. The companies implement both organic (such as product launches, expansion, and product approvals) and inorganic (such as collaborations and partnerships) strategies to stay competitive in the market.   

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com